Study summary · research use only
Current Evidence of Acetyl-L-Carnitine Use in Mood Disorders-: A Systematic Review and Meta-Analysis
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This systematic review and meta-analysis examined Acetyl-L-carnitine (ALC) use in mood disorders, including major depressive disorder and bipolar disorder, drawing on randomized controlled trials, open-label studies, and observational research. The systematic review included 15 studies and the meta-analysis included 10 studies (14 randomized controlled trials and 1 open-label study), covering 809 participants (392 in treatment groups, 417 in comparator groups). The authors report that ALC was associated with reduced depressive symptoms compared with placebo, with outcomes described as comparable to standard antidepressants and fewer adverse effects, and that subgroup analyses suggested larger differences in older adults and those with treatment-resistant depression. The authors state further large-scale, longitudinal studies are needed to clarify ALC's clinical utility and mechanistic pathways in mood disorders.
Abstract
Acetyl-l-carnitine (ALC) is increasingly recognized for its potential psychopharmacological mechanism and role in the treatment of mood disorders, particularly major depressive disorder (MDD) and bipolar disorder (BD). Emerging evidence suggests that ALC levels are reduced in individuals with MDD, and this deficiency may contribute to depressive symptoms through disruptions in mitochondrial fatty acid transport, neuroplasticity, and neurotransmission. This review synthesizes findings from randomized controlled trials, open-label studies, and observational research examining ALC use and clinical outcomes in adults treated with ALC in MDD and BD. A systematic review (n=15) and meta-analysis (n=10) studies (14 randomized controlled trials [RCTs] and 1 open label) involving 809 participants (treatment group: 392; comparator group: 417) revealed that ALC significantly reduces depressive symptoms compared to placebo, with comparable efficacy to standard antidepressants and fewer adverse effects. Subgroup analyses suggest enhanced benefits in older adults and those with treatment-resistant depression. These findings support the potential of ALC as both a biomarker and a therapeutic agent in mood disorders. Further large-scale, longitudinal studies are needed to clarify its clinical utility and mechanistic pathways in mood disorders.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.